Binixen 15 Mg (Binimetinib) Tablets

Introduction

Binixen 15 mg (Binimetinib) is a high-potency, targeted oncology medication belonging to the class of MEK (mitogen-activated protein kinase) inhibitors. Manufactured by Everest Pharmaceuticals Ltd. and supplied by Orio Pharma, Binixen is a critical component in the treatment of cancers driven by specific genetic mutations. It is primarily used in combination with other targeted therapies to block the signals that cause cancer cells to multiply, offering a specialized approach for patients with advanced melanoma and lung cancer.

Indications

Binixen 15 mg (Binimetinib) is indicated for:

Unresectable or Metastatic Melanoma: For the treatment of adult patients with BRAF V600E or V600K mutations, typically used in combination with Encorafenib.
Metastatic Non-Small Cell Lung Cancer (NSCLC): For adult patients whose tumors have a BRAF V600E mutation.

Pharmacology

Binimetinib, the active ingredient in Binixen, is a reversible inhibitor of MEK1 and MEK2. These enzymes are essential parts of the MAPK signaling pathway, which regulates cell growth. In tumors with BRAF mutations, this pathway is overactive.

Mechanism of Action: By inhibiting MEK1/2, Binixen disrupts the signaling chain, leading to a decrease in tumor cell proliferation and an increase in cancer cell death (apoptosis).
Efficacy: When used alongside a BRAF inhibitor, Binimetinib helps overcome resistance and provides a more comprehensive blockade of the cancer’s growth pathway.

Dosage & Administration

Oral Administration for Adults:

Recommended Dose: 45 mg (three 15 mg tablets) taken orally twice daily, approximately 12 hours apart.
Administration: Tablets may be taken with or without food.
Missed Dose: If a dose is missed within 6 hours of the next scheduled dose, skip the missed dose and resume the regular schedule.
Note: Treatment should be initiated and supervised by an oncology specialist experienced in targeted therapies.

Drug Interactions

UGT1A1 Inducers: May reduce the effectiveness of Binimetinib.
Hormonal Contraceptives: Potential interactions may occur; non-hormonal birth control is recommended.
Note: Always inform your doctor of all supplements and over-the-counter medications being taken.

Contraindications

Hypersensitivity: Known severe allergy to Binimetinib or any of the tablet’s inactive ingredients.
Pregnancy: Categorized as a risk to the fetus; not recommended during pregnancy.

Side Effects

Patients receiving Binixen 15 mg may experience:

Gastrointestinal: Nausea, diarrhea, and vomiting.
Ocular: Visual disturbances, such as blurred vision or retinal pigment epithelial detachment (RPED).
Musculoskeletal: Increased levels of blood creatine phosphokinase (CPK), muscle pain, or weakness.
Systemic: Fatigue, dizziness, and peripheral edema (swelling of the hands or feet).

Pregnancy & Lactation

Pregnancy: Effective non-hormonal contraception is mandatory during treatment and for at least 30 days after the final dose.
Lactation: Breastfeeding is discouraged during treatment and for a short period after the last dose to ensure infant safety.

Precautions & Warnings

Cardiac Health: Regular monitoring of Left Ventricular Ejection Fraction (LVEF) is required as the drug may affect heart function.
Ophthalmological Monitoring: Patients should report any changes in vision immediately; regular eye exams are recommended.
Liver Function: Periodic blood tests to monitor liver enzymes (ALT/AST) are necessary.
Blood Clots: Monitor for signs of venous thromboembolism (VTE) or pulmonary embolism.

Use in Special Populations

Hepatic Impairment: Patients with moderate to severe liver impairment may require a dose reduction to 30 mg twice daily.
Pediatric Use: The safety of Binimetinib has not been established in children under 18 years of age.

Overdose Effects

Overdose may lead to severe gastrointestinal issues, skin toxicity, or cardiac complications. If an overdose is suspected, seek immediate medical attention for supportive care.

Storage

Conditions: Store at controlled room temperature (20°C to 25°C).
Protection: Keep tablets in the original blister pack or bottle to protect from light and moisture. Keep out of reach of children.

Supplier Information

Orio Pharma is a trusted pharmaceutical supplier dedicated to providing reliable access to advanced oncology treatments. We bridge the gap between world-class manufacturing and patient needs. For more information or to request a quote, visit our official channels.

Manufacturer Information

Binixen 15 mg is manufactured by Everest Pharmaceuticals Ltd., a premier manufacturer based in Bangladesh, renowned for its commitment to high-quality specialized generics and advanced oncology solutions.